Palynziq ( DrugBank: - )

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
240フェニルケトン尿症3

240. フェニルケトン尿症

臨床試験数 : 143 /  薬物数 : 90 - (DrugBank : 10) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 5
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT05579548
(ClinicalTrials.gov)		October 4, 202211/10/2022A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and BreastfeedingA Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and BreastfeedingPhenylketonuria, MaternalDrug: PegvaliaseBioMarin PharmaceuticalSyneos HealthRecruitingN/AN/AFemale50United States
2NCT05356377
(ClinicalTrials.gov)		May 25, 202227/4/2022Preliminary Study of Brain Effects of Palynziq-Related Changes in Phenylalanine in Individuals With PKUA Preliminary Study of the Neurological and Neuropsychological Effects of Palynziq-Related Changes in Phenylalanine in Individuals With Phenylketonuria (PKU)PhenylketonuriasDrug: Pegvaliase-PqpzUniversity of Missouri-ColumbiaBioMarin PharmaceuticalEnrolling by invitation18 Years55 YearsAll13United States
3NCT04404530
(ClinicalTrials.gov)		October 8, 201921/5/2020Nutritional Impacts of Palynziq on Patients With Phenylketonuria (PKU)Palynziq and PKU: Treatment Impacts on Diet Quality, Neurological Health, Nutritional Status, and the MetabolomePhenylketonuriasDrug: PalynziqEmory UniversityBioMarin PharmaceuticalRecruiting16 YearsN/AAll45United States